Asset Details
Do you wish to reserve the book?
Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
Do you wish to request the book?
Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Causes of drug-induced photosensitivity: an analysis using FDA adverse event reporting system database
2025
Overview
The purpose of this study is to analyze FAERS data to identify cases of drug-induced photosensitivity (DIP), examine demographic patterns, determine the drug classes involved, and highlight emerging trends in these reactions. Additionally, we explore potential signal drugs by mining the relevant reported data, aiming to provide insights for safer clinical use of medications. We reviewed the publicly available FAERS database from 2004 to 2023. Using DIP-related search terms such as “photosensitivity reaction,” “polymorphic light eruption,” or et al., we identified reports of DIP. The frequency and trends of these reports were then analyzed. Between 2004 and 2023, the FDA received 17,384,824 reports of adverse reactions, with 20,236 of these linked to DIP. After excluding cases with incomplete data on age, gender, or country of origin, the median patient age was 52 years (IQR = 66). Females comprised 55.71% of the cases (11,274), and 66.96% (12,459) of the reports originated from the United States. The top 45 drugs were responsible for 9,810 cases (48.48%). The three drug classes most commonly associated with DIP in the FAERS database were immunosuppressants, monoclonal antibodies, and antineoplastic agents. A disproportionality analysis of the top drugs revealed several newly identified drugs with signals for photosensitivity, including adalimumab, adapalene, secukinumab, and fingolimod. By analyzing publicly available FAERS data, we identified key themes and trends in DIP reactions. Immunosuppressants and monoclonal antibodies show mild trends in DIP occurrence. Additionally, adalimumab, adapalene, secukinumab, and fingolimod are novel drug signals of DIP.
Publisher
Nature Publishing Group UK,Nature Publishing Group,Nature Portfolio
Subject
/ Adult
/ Adverse Drug Reaction Reporting Systems - statistics & numerical data
/ Aged
/ Child
/ Drug-induced photosensitivity
/ Drug-Related Side Effects and Adverse Reactions - epidemiology
/ Drugs
/ FDA
/ Female
/ Humanities and Social Sciences
/ Humans
/ Male
/ Photosensitivity Disorders - chemically induced
/ Photosensitivity Disorders - epidemiology
/ Science
/ Trends
